Ypsomed Holding (YPSN) Stock Overview
Develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
YPSN Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Ypsomed Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 287.00 |
| 52 Week High | CHF 441.50 |
| 52 Week Low | CHF 260.50 |
| Beta | 0.76 |
| 1 Month Change | 2.87% |
| 3 Month Change | -14.07% |
| 1 Year Change | -11.01% |
| 3 Year Change | 42.79% |
| 5 Year Change | 80.05% |
| Change since IPO | 287.84% |
Recent News & Updates
Recent updates
Ypsomed Holding AG's (VTX:YPSN) Business Is Yet to Catch Up With Its Share Price
Jan 20
Here's Why We Think Ypsomed Holding (VTX:YPSN) Is Well Worth Watching
Jan 07Ypsomed Holding (VTX:YPSN) Is Investing Its Capital With Increasing Efficiency
Dec 19When Should You Buy Ypsomed Holding AG (VTX:YPSN)?
Nov 17Ypsomed Holding AG's (VTX:YPSN) Share Price Is Still Matching Investor Opinion Despite 25% Slump
Oct 18Ypsomed Holding (VTX:YPSN) Might Have The Makings Of A Multi-Bagger
Aug 20Investors Appear Satisfied With Ypsomed Holding AG's (VTX:YPSN) Prospects
Aug 07We Think Ypsomed Holding (VTX:YPSN) Can Stay On Top Of Its Debt
Jul 24Do Ypsomed Holding's (VTX:YPSN) Earnings Warrant Your Attention?
Jul 11Is Now An Opportune Moment To Examine Ypsomed Holding AG (VTX:YPSN)?
Jun 11Ypsomed Holding's (VTX:YPSN) Shareholders May Want To Dig Deeper Than Statutory Profit
May 29Earnings Miss: Ypsomed Holding AG Missed EPS By 18% And Analysts Are Revising Their Forecasts
May 24Returns At Ypsomed Holding (VTX:YPSN) Are On The Way Up
Apr 30
GLP-1 Partnerships And Capacity Expansion To Drive Revenue Growth And Boost Margins
Ypsomed's shift to a B2B model and local manufacturing may streamline operations, improve focus, and reduce geopolitical risks, enhancing margins and earnings.Shareholder Returns
| YPSN | CH Medical Equipment | CH Market | |
|---|---|---|---|
| 7D | 2.7% | 1.7% | 1.8% |
| 1Y | -11.0% | -15.0% | 15.1% |
Return vs Industry: YPSN exceeded the Swiss Medical Equipment industry which returned -13.2% over the past year.
Return vs Market: YPSN underperformed the Swiss Market which returned 17.5% over the past year.
Price Volatility
| YPSN volatility | |
|---|---|
| YPSN Average Weekly Movement | 4.6% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in CH Market | 8.2% |
| 10% least volatile stocks in CH Market | 2.3% |
Stable Share Price: YPSN has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: YPSN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 2,000 | Simon Michel | www.ypsomed.com |
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices.
Ypsomed Holding AG Fundamentals Summary
| YPSN fundamental statistics | |
|---|---|
| Market cap | CHF 3.92b |
| Earnings (TTM) | CHF 194.00m |
| Revenue (TTM) | CHF 787.55m |
Is YPSN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YPSN income statement (TTM) | |
|---|---|
| Revenue | CHF 787.55m |
| Cost of Revenue | CHF 478.09m |
| Gross Profit | CHF 309.46m |
| Other Expenses | CHF 115.46m |
| Earnings | CHF 194.00m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
May 20, 2026
| Earnings per share (EPS) | 14.22 |
| Gross Margin | 39.29% |
| Net Profit Margin | 24.63% |
| Debt/Equity Ratio | 1.2% |
How did YPSN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/13 10:01 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ypsomed Holding AG is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pallav Mittal | Barclays |
| Gaurav Jain | Barclays |
| Odysseas Manesiotis | BNP Paribas |